Johnson & Johnson’s final phase of AIDS vaccine trial results fail, throwing off vaccine hope Have to go back and count once more to find a new experimental vaccine.
Jenson Pharmaceutical Company Announced to end phase 3 trials of an AIDS vaccine following the results showed that the vaccine was not effective enough to prevent HIV/AIDS infection. It is the only AIDS vaccine currently making the most progress in human trials. However, scientists are confident that it is possible to produce other new vaccines.
The vaccine trial, dubbed Mozygo, began a phase 3 trial in 2019 with a total of 3,900 volunteers, both males and females. and transgender people in 50 areas from 9 countries in North America, South America and Europe: Argentina, Brazil, Italy, Mexico, Peru, Poland, Puerto Rico, Spain and the United States. Previously, many experimental vaccines had failed during testing in the past 30 years. It can be regarded as the hope of an AIDS vaccine in the past three to five years. However, researchers remain hopeful. There are still options from other vaccines still in early trials that may be able to prevent future infections.
Dr. Anthony S. Fuzi, director of the National Institute of Infectious Diseases, said: The news is disappointing. But this does not mean the end of the vaccine development effort. because there are also other strategic plans He was referring to a research study called PrEPVacc in East Africa and South Africa. There is a trial using a test vaccine along with anti-infection drugs. The researchers are developing effective antibodies. that can reduce the spread of the virus The new vaccine will use new vaccine production technology. Including mRNA technology to prevent HIV infection. pharmaceuticals This is a challenge in the development of an AIDS vaccine. Since the disease was first discovered 40 years ago, it has been estimated that the annual number of infections worldwide exceeds 1.5 million and the death toll exceeds 650,000. Globally, 40 million are infected, and 10 million have no access to treatment.
For a rich country AIDS may not be a public health concern. Because they have access to drugs that are highly effective in suppressing the infection. There are also several other treatment options, such as oral pills or bi-monthly injections, which are regarding to be approved for use in the United States. Or injectable drugs that are used every 6 months are in the final stages of the experiment, etc. However, This treatment is a lifelong treatment. and some people are unable to access treatment Therefore, a safe and effective vaccine is the best solution to prevent such diseases.
Jenson Pharmaceutical Co. In a statement, the company, which is part of Johnson & Johnson, announced the results of a phase 3 evaluation of the vaccine trial following an independent review of its monitoring and safety committee. In conclusion, the experimental vaccine was not effective in preventing HIV infection when compared to a placebo given to the volunteer group. The safety of the experimental vaccine has not yet been detailed. From the results of the conclusions from the said committee. Company halts phase 3 human trials of AIDS vaccine
“We regret this conclusion. But we remain united with communities vulnerable to the impact of HIV infection. Despite significant advances in disease prevention following a global pandemic, 1.5 million people were infected worldwide by 2021. This reinforces that we need to address global public health issues. We remain committed to developing new innovations in the treatment of AIDS. Mosaigo continues to work in depth to develop safe and effective vaccines. And the company would like to thank all those involved in the research and development of the vaccine trial, ” said Penny Heaton, head of vaccine development. of the Jenson Company pharmaceutical said
Conclusions from an independent committee on monitoring data and safety This is in line with the results of a phase 2 trial announced in August 2021 that the trial vaccine was not effective in preventing infection among adolescent women in sub-Saharan Africa. of Africa But the vaccine is still safe.
However, previous research has found that an experimental HIV vaccine can create immunity that can significantly reduce the spread of the virus. This is the first discovery that such a vaccine can produce the desired effect. The study, published in the journal Science, involved 48 healthy volunteers who received two doses of the vaccine and two placebo vaccines. A tangible increase in the first batch of immune cells was found. before expanding into a perfect immune system which researchers believe The findings proved the hypothesis. that the vaccine works effectively in inhibiting infection will have such behavior
Source: The Only HIV Vaccine in Advanced Trials Has Failed. What Now?, New York Times
Photo: Getty
